Stem cell-derived erythroid cells mediate long-term systemic protein delivery

Nature Biotechnology

Volumn 24, Issue 8, 2006, Pages 1017-1021

  Chang, Alex H ^a   Stephan, Matthias T ^a,b   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; IMMUNOLOGY; ONCOLOGY; PROTEINS;

ERYTHROPOIESIS; HUMAN FACTOR IX (HFIX); STEM CELLS; TRANSCRIPTIONAL SILENCING;

CELLS;

LENTIVIRUS VECTOR; PROTEIN ARGININE METHYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING DISORDER; CARCINOGENESIS; CELL BASED GENE THERAPY; CONTROLLED STUDY; ERYTHROID CELL; EX VIVO STUDY; GENE SILENCING; HEMATOPOIETIC STEM CELL; HEMOPHILIA B; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; STEM CELL;

ANIMALS; CELLS, CULTURED; ERYTHROID CELLS; FACTOR IX; GENETIC ENHANCEMENT; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED C57BL; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 33747076039     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1227     Document Type: Article

References (30)

1. Ganong, W.F.. Review of Medical Physiology, edn. 20 (Lange Medical Books/McGraw-Hill, New York, 2001).
2. Wang, L. et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc. Natl. Acad. Sci. USA 94, 11563-11566 (1997).
3. Mannucci, P.M. & Tuddenham, E.G. The hemophilias - from royal genes to gene therapy. N. Engl. J. Med. 344, 1773-1779 (2001).
4. May, C. et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 406, 82-86 (2000).
5. Kurachi, S., Hitomi, Y., Furukawa, M. & Kurachi, K. Role of intron I in expression of the human factor IX gene. J. Biol. Chem. 270, 5276-5281 (1995).
6. Woods, N.B. et al. Lentiviral-mediated gene transfer into haematopoietic stem cells. J. Intern. Med. 249, 339-343 (2001).
7. Challita, P.M. & Kohn, D.B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. USA 91, 2567-2571 (1994).
8. Liu, Y., Nelson, A.N. & Lipsky, J.J. Vitamin K-dependent carboxylase: mRNA distribution and effects of vitamin K-deficiency and warfarin treatment. Biochem. Biophys. Res. Commun. 224, 549-554 (1996).
9. Samakoglu, S. et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat. Biotechnol. 24, 89-94 (2006).
10. Kootstra, N.A., Matsumura, R. & Verma, I.M. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol. Ther. 7, 623-631 (2003).
11. Evans, G.L. & Morgan, R.A. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc. Natl. Acad. Sci. USA 95, 5734-5739 (1998).
12. Moayeri, M., Hawley, T.S. & Hawley, R.G. Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol. Ther. 12, 1034-1042 (2005).
13. Heim, D.A. & Dunbar, C.E. Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency. Immunol. Rev. 178, 29-38 (2000).
14. Bagley, J., Bracy, J.L., Tian, C., Kang, E.S. & Iacomini, J. Establishing immunological tolerance through the induction of molecular chimerism. Front. Biosci. 7, d1331-d1337 (2002).
15. Bennett, B., Check, I.J., Olsen, M.R. & Hunter, R.L. A comparison of commercially available adjuvants for use in research. J. Immunol. Methods 153, 31-40 (1992).
16. Herzog, R.W. et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94, 5804-5809 (1997).
17. Axelrod, J.H., Read, M.S., Brinkhous, K.M. & Verma, I.M. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc. Natl. Acad. Sci. USA 87, 5173-5177 (1990).
18. Rodriguez, M.H. et al. Expression of coagulation factor IX in a haematopoietic cell line. Thromb. Haemost. 87, 366-373 (2002).
19. Li, Q., Peterson, K.R., Fang, X. & Stamatoyannopoulos, G. Locus control regions. Blood 100, 3077-3086 (2002).
20. Kikuchi, J. et al. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. J. Gene Med. 6, 1049-1060 (2004).
21. Tiede, A. et al. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther. 10, 1917-1925 (2003).
22. Hoeben, R.C. et al. Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb. Haemost. 67, 341-345 (1992).
23. Bigger, B.W. et al. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Ther. 13, 117-126 (2006).
24. Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
25. Kohn, D.B., Sadelain, M. & Glorioso, J.C. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer 3, 477-488 (2003).
26. von Kalle, C., Baum, C. & Williams, D.A. Lenti in red: progress in gene therapy for human hemoglobinopathies. J. Clin. Invest. 114, 889-891 (2004).
27. Sadelain, M. Insertional oncogenesis in gene therapy: how much of a risk? Gene Ther. 11, 569-573 (2004).
28. Giarratana, M.C. et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat. Biotechnol. 23, 69-74 (2005).
29. Ng, E.S., Davis, R.P., Azzola, L., Stanley, E.G. & Elefanty, A.G. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 106, 1601-1603 (2005).
30. Margaritis, P. et al. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J. Clin. Invest. 113, 1025-1031 (2004).